ALKERMES, INC.
Lobbying client. Federal LDA filings.
- Source id
202088- General description
- Global biopharmaceutical company
- State
- DC
- Country
- US
- Principal place of business
- US
- Government-entity client
- false
- Effective date
- 2017-08-02
- Total spend (across 1 ingested filings)
- $60,000
Filings (1) — $60,000
| Posted | Type | Year | Lobbying firm | Income |
|---|---|---|---|---|
| 2026-04-20 | Q1 | 2026 | SPLITOAK STRATEGIES LLC | $60,000 |
Connected on the graph
10 typed relationships in the influence graph — 10 inbound, 0 outbound, grouped by type.
lobbied for (10)
| date | dir | entity | amount | role | source |
|---|---|---|---|---|---|
| — | ← | Sarah Kuehl Egge | — | lda_lobbyist_client | |
| — | ← | Daniel M Todd | — | lda_lobbyist_client | |
| — | ← | Zachary Michael Marshall | — | lda_lobbyist_client | |
| — | ← | William Patrick Hibbs | — | lda_lobbyist_client | |
| — | ← | Katherine Fleming Cotton | — | lda_lobbyist_client | |
| — | ← | Eric Bergren | — | lda_lobbyist_client | |
| — | ← | Ted Lehman | — | lda_lobbyist_client | |
| — | ← | Peter Norman | — | lda_lobbyist_client | |
| — | ← | Paul Edattel | — | lda_lobbyist_client | |
| — | ← | Nicholas Uehlecke | — | lda_lobbyist_client |